Business Context and Reporting Period
Company: Context Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2026
Reporting Period: Event date July 29, 2026; Signed July 31, 2026
Business Context: The Company is an emerging growth company incorporated in Delaware with common stock (Symbol: CNTX) listed on The Nasdaq Stock Market.
Key Financial Metrics
This filing is a current report regarding a listing deficiency and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the receipt of a Notification Letter from the Nasdaq Listing Qualifications Department on July 29, 2026. The Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Rule) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
Guidance, Outlook, and Risks
- Compliance Timeline: The Company has an initial 180-calendar-day period to regain compliance, ending January 25, 2027.
- Compliance Requirement: To regain compliance, the stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.
- Second Compliance Period: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period, contingent on meeting market value of publicly held shares requirements and notifying Nasdaq of intent to cure.
- Delisting Risk: Failure to regain compliance within the allotted periods may result in delisting. The Company may appeal a delisting determination, but success is not assured.
- Management Commentary: The Company intends to actively monitor the closing bid price and evaluate options to resolve the deficiency. No assurance is given that compliance will be achieved.
Investor Verification Checklist
- Verify the current closing bid price of CNTX stock relative to the $1.00 threshold.
- Monitor the Company's ability to maintain a $1.00+ closing price for 10 consecutive business days before January 25, 2027.
- Review the Company's most recent Form 10-K for detailed financial health and liquidity status, as this 8-K does not provide financial data.
- Watch for future announcements regarding a reverse stock split or other capital actions intended to address the bid price deficiency.
- Confirm whether the Company files a notice of intent to cure for a Second Compliance Period if the initial deadline is missed.